Compounded tirzepatide dosing “units” on an insulin syringe
Reports of injecting “100 units” of compounded tirzepatide (including products sold as tirzepatide or branded as Mounjaro) most commonly refer to the syringe scale units on an insulin syringe, which are primarily a measurement of injected volume, not a measurement of tirzepatide milligrams. [1][2]
Meaning of “100 units” on a standard insulin syringe
On a U-100 insulin syringe, 100 units equals 1 mL of liquid volume. [2][3]
Why the tirzepatide amount cannot be determined from “100 units” alone
For compounded GLP-1 therapies, FDA has warned that instructions may use “units” (volume) rather than milligrams, and the concentration of the compounded solution can vary, so the mg dose depends on the labeled concentration (mg/mL) of the vial. [1]
Conversion needed: units to mL to milligrams
The injected volume is determined by the syringe scale (for U-100 syringes: units ÷ 100 = mL). [2][3]
The tirzepatide milligram dose equals (mL injected) × (tirzepatide concentration in mg/mL), which requires the vial’s concentration label. [1][2]
Key safety implication
Using syringe “units” without confirming the vial concentration has been associated with medication dosing errors for compounded injectable GLP-1 products, including errors arising from conversion between milligrams and other measurement systems. [1]
Immediate clarification steps for dose verification
- The vial label concentration (mg/mL) should be confirmed directly from the pharmacy dispensing label or vial. [1]
- The syringe type should be confirmed as U-100 (since unit-to-volume relationships differ by syringe calibration). [2][3]
- The resulting mg dose should be compared with the prescribed tirzepatide dose schedule (mg per injection) to verify correctness. [1]
When urgent reassessment is needed
Urgent reassessment is warranted when a dosing error is suspected, because FDA reports included patients who required medical attention after compounded GLP-1 dosing errors. [1]